Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,774.00-1.79%ETH$2,476.01-3.60%GOLD$4,158.80+0.04%OIL$90.94-0.60%
Smart Investors Daily
SID Premium
Marker Therapeutics, Inc. logo

NASDAQ · MRKR

Marker Therapeutics, Inc.

Healthcare · Biotechnology

$1.04

Down-$0.09 (-8.65%)

Updated Oct 8, 2026, 10:17 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.39M
P/E ratio
-1.67
Dividend yield
0.00%
52-week range
$0.98 – $1.79
Volume
37.47K
Avg. volume
265.93K

Price performance · MRKR

MRKR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

MRKR closed at $1.04 after 21 trading sessions, down 14.05% for the selected period.

Last close
$1.04
Period change
-14.05%
Period low
$1.01
Period high
$1.24
Daily close
View OHLC price history
MRKR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$1.03$1.06$1.03$1.0437.47K
Oct 6, 2026$1.07$1.07$1.0041$1.0177.14K
Oct 5, 2026$1.08$1.085$1.045$1.0673.49K
Oct 2, 2026$1.06$1.08$1.02$1.05100.29K
Oct 1, 2026$1.08$1.09$0.981$1.05127.49K
Sep 30, 2026$1.12$1.14$1.07$1.0738.39K
Sep 29, 2026$1.14$1.16$1.075$1.1090.89K
Sep 28, 2026$1.12$1.15$1.07$1.125164.34K
Sep 25, 2026$1.22$1.22$1.15$1.1530.66K
Sep 24, 2026$1.2599$1.31$1.15$1.19141.64K
Sep 23, 2026$1.24$1.27$1.23$1.2464.91K
Sep 22, 2026$1.18$1.235$1.18$1.2238.96K
Sep 21, 2026$1.18$1.22$1.18$1.2024.23K
Sep 18, 2026$1.19$1.23$1.17$1.1847.27K
Sep 17, 2026$1.13$1.225$1.13$1.1860.6K
Sep 16, 2026$1.17$1.18$1.13$1.1435.87K
Sep 15, 2026$1.17$1.23$1.15$1.1711.98K
Sep 14, 2026$1.16$1.2302$1.16$1.1717.38K
Sep 11, 2026$1.20$1.245$1.10$1.1559.37K
Sep 10, 2026$1.21$1.23$1.18$1.2055.52K
Sep 9, 2026$1.29$1.29$1.21$1.2171.16K

Latest MRKR news

The latest Smart Investors Daily articles mentioning MRKR.

Stock researchCompany · Overview

MRKR research

Overview

Company profile and research snapshot.

Company profile

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MRKR recent ratings
DateFirmRatingTarget
Dec 8, 2025HC Wainwright & Co.Buy—
Apr 1, 2025WBB SecuritiesStrong Buy—
Mar 5, 2025Canaccord GenuityBuy—
Oct 21, 2024Ladenburg ThalmannBuy—
Apr 30, 2024Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therap

Yahoo · Jun 5, 2026

Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has remained flat, yet it is up 26% over the past year with earnings expected to grow by 16% per annum over the next few years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and strong potential to capitalize on future market trends.

Yahoo · Jun 5, 2026

US High Growth Tech Stocks with Promising Potential

In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 26%, with earnings expected to grow by 16% per annum in the coming years. In this environment of steady growth and promising earnings projections, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging technological trends.

Yahoo · Jun 2, 2026

3 High Growth Tech Stocks To Watch In The US Market

Over the last 7 days, the United States market has risen 1.6%, and in the past year, it has climbed 28%, with earnings anticipated to grow by 17% per annum over the next few years. In such a dynamic environment, identifying high growth tech stocks that align with these positive trends can be crucial for investors looking to capitalize on potential opportunities in this sector.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By